ODM-201 vs Androgen Deprivation Therapy in Hormone naïve Prostate Cancer

Summary

This is an open label non-comparative controlled randomized phase II study. The experimental arm is the group receiving ODM-201. The group receiving androgen-deprivation therapy (ADT) is included as an internal control. The primary trial objective is to demonstrate that ODM-201 produces prostate-specific antigen (PSA) response rates at 24 weeks (defined as ≥80% reduction compared to baseline) that are in the range of those achieved with 24 weeks of ADT. In total, this 1:1 randomized study will therefore require randomization of at least 250 patients, 125 to each arm.

Timeline

Start

2017-12-01

Primary completion

2023-01-13

Completion

2036-12

Drugs

Indications